Tags

Type your tag names separated by a space and hit enter

The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Neurol Neurochir Pol. 2001; 35 Suppl 3:65-8.NN

Abstract

Dyskinesias are the most frequent adverse effect of chronic levodopa therapy in patients with Parkinson's disease (PD). Current pharmacological treatment for this problem is unsatisfactory. Recently, there is evidence for the role of glutamate in the basal ganglia neuronal circuitry in the generation of dyskinesias. If indeed glutamatergic overactivity beyond the dopaminergic synapses plays a role in the pathogenesis of these involuntary movements, there is hope that its suppression may be beneficial without causing loss of levodopa efficacy and parkinsonian deterioration. Indeed, NMDA receptor antagonists such as amantadine and dextrometorphan can reduce such dyskinesias. We tested the efficacy of riluzole, an inhibitor of glutamatergic transmission in the inhibition of levodopa-induced dyskinesias.

Authors+Show Affiliations

Department of Neurology, Rabin Medical Center, Belinson Campus, Petah Tikva.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12001656

Citation

Merims, D, et al. "The Role of Glutamatergic Transmission in the Pathogenesis of Levodopa-induced Dyskinesias. Potential Therapeutic Approaches." Neurologia I Neurochirurgia Polska, vol. 35 Suppl 3, 2001, pp. 65-8.
Merims D, Ziv I, Sherki Y, et al. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches. Neurol Neurochir Pol. 2001;35 Suppl 3:65-8.
Merims, D., Ziv, I., Sherki, Y., Djaldetti, R., & Melamed, E. (2001). The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches. Neurologia I Neurochirurgia Polska, 35 Suppl 3, 65-8.
Merims D, et al. The Role of Glutamatergic Transmission in the Pathogenesis of Levodopa-induced Dyskinesias. Potential Therapeutic Approaches. Neurol Neurochir Pol. 2001;35 Suppl 3:65-8. PubMed PMID: 12001656.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches. AU - Merims,D, AU - Ziv,I, AU - Sherki,Y, AU - Djaldetti,R, AU - Melamed,E, PY - 2002/5/11/pubmed PY - 2002/7/18/medline PY - 2002/5/11/entrez SP - 65 EP - 8 JF - Neurologia i neurochirurgia polska JO - Neurol Neurochir Pol VL - 35 Suppl 3 N2 - Dyskinesias are the most frequent adverse effect of chronic levodopa therapy in patients with Parkinson's disease (PD). Current pharmacological treatment for this problem is unsatisfactory. Recently, there is evidence for the role of glutamate in the basal ganglia neuronal circuitry in the generation of dyskinesias. If indeed glutamatergic overactivity beyond the dopaminergic synapses plays a role in the pathogenesis of these involuntary movements, there is hope that its suppression may be beneficial without causing loss of levodopa efficacy and parkinsonian deterioration. Indeed, NMDA receptor antagonists such as amantadine and dextrometorphan can reduce such dyskinesias. We tested the efficacy of riluzole, an inhibitor of glutamatergic transmission in the inhibition of levodopa-induced dyskinesias. SN - 0028-3843 UR - https://www.unboundmedicine.com/medline/citation/12001656/The_role_of_glutamatergic_transmission_in_the_pathogenesis_of_levodopa_induced_dyskinesias__Potential_therapeutic_approaches_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -